Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 31;7:14701. doi: 10.1038/s41598-017-14822-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Cardioprotection induced by MLC901 in vivo at the acute phase of myocardial ischemia-reperfusion. (A,D) Experimental protocols: mice underwent a surgical protocol of myocardial 40 min-ischemia followed by 1h-reperfusion (IR; panel A) or 24h-reperfusion (IR_24h; panel D). Injection of MLC901 (0.4, 4 or 40 µg/kg) was performed intravenously 5 minutes before the onset of reperfusion. Infarct size measurement was performed at the end of reperfusion. (B) Scatter dot blots and means ± SD were plotted for infarct size (in % of area at risk). When mice were treated with MLC901 at 4 µg/kg, a 49.8%-decrease in infarct size was observed. A smaller cardioprotective effect was observed for the treatment with 0.4 µg/kg MLC901. This cardioprotective effect was not observed with 40 µg/kg MLC901. (C) Scatter dot blots and means ± SD were plotted for AR/LV mass. (D) IR_24h animals received MLC901 (4 µg/kg) or physiological saline serum alone (IR). (E) Scatter dot blots and means ± SD were plotted for infarct size (in % of area at risk). (F) Scatter dot blots and means ± SD were plotted for AR/LV mass. Statistical analysis was performed using ANOVA test with the Tukey’s post hoc test for multiple comparisons or Mann-Whitney test for comparisons between 2 groups.